Related Experiment Videos
Risk factors for neuroleptic malignant syndrome. A case-control study
P E Keck1, H G Pope, B M Cohen
1Biological Psychiatry Laboratory, Mailman Research Center, McLean Hospital, Belmont, Mass.
Archives of General Psychiatry
|October 1, 1989
Summary
Neuroleptic Malignant Syndrome (NMS) risk factors were studied. Patients with NMS showed more agitation, higher neuroleptic doses, and more injections than controls, suggesting these are key risk factors.
Area of Science:
- Neuroscience
- Psychiatry
- Clinical Pharmacology
Background:
- Neuroleptic Malignant Syndrome (NMS) is a rare but serious adverse reaction to neuroleptic medications.
- Proposed risk factors for NMS lack controlled investigation, hindering preventative strategies.
Purpose of the Study:
- To identify potential risk factors for Neuroleptic Malignant Syndrome through a controlled case-control study.
- To compare clinical characteristics and treatment parameters between NMS patients and matched controls.
Main Methods:
- A case-control study design was employed.
- 18 patients diagnosed with NMS were compared to 36 matched neuroleptic-treated control patients without a history of NMS.
- Data collected included psychomotor agitation levels, neuroleptic dosage, rate of dosage increase, and administration routes (oral vs. intramuscular).
Main Results:
- Patients with NMS exhibited significantly higher levels of psychomotor agitation compared to controls.
- NMS patients received significantly higher doses of neuroleptics and experienced faster rates of dosage increase.
- A greater number of intramuscular injections were administered to patients who developed NMS.
Conclusions:
- Psychomotor agitation, high-dose neuroleptics, rapid dose escalation, and frequent intramuscular injections are significant risk factors associated with the development of Neuroleptic Malignant Syndrome.
- These findings highlight crucial factors for clinicians to consider in NMS prevention and management.